Fig. 2From: Cost-effectiveness of sacituzumab govitecan versus single-agent chemotherapy for metastatic triple-negative breast cancer: a trial-based analysisState membership in a 3-state partitioned survival model. (Note: OS, overall survival; PFS, progression-free survival)Back to article page